Coronavirus: Swissmedic grants Lonza in Visp another establishment licence for the production of COVID-19 active substances

21. März 2021 – Swissmedic has granted the chemicals and pharmaceuticals company Lonza an establishment licence for a new production site for the manufacture of Moderna's COVID-19 active substance. The licence was issued last week following a successful inspection of the production plant in Visp. At this newly approved site Lonza can manufacture, on behalf of Moderna, active substances for COVID-19 vaccines.

For more information, see here.